Alterity Therapeutics Ltd ATHE shares are trading higher by 5.67% to $4.12 Monday morning after the company announced ATH434 prevents loss of brain cells in Parkinson's Disease animal model.
Among findings, Alterity says the study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice. The company says the authors also demonstrated that ATH434 prevented the development of motor impairment in older animals, which was associated with a reduction in iron levels and preservation of neurons in the substantia nigra, the brain region affected in Parkinson's.
See Also: Why CN Energy Group Shares Are Getting Hammered
Alterity added these data support other studies indicating that ATH434 has a beneficial effect on the motor and non-motor symptoms in animal models of PD.
According to data from Benzinga Pro, ATHE has a 52-week high of $10.50 and a 52-week low of $2.90.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.